Advertisement
Screener

VERU INC. (VERU) Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs

2.2 / 5 stars · 40/89 Roast Me

VERU INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs

VERU INC. (VERU) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $4.10 million as of 2019-09-30, per its 10-K filed 2020-12-10.

Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross

us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2020-12-10

  • 2019-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $4.10M.
Period endDeferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
2019-09-30$4.10M
10-K · filed 2020-12-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kairos Pharma, LTD. (KAPA)United States$0.041B
SCYNEXIS INC (SCYX)United States$0.045B
PDS Biotechnology Corp (PDSB)United States$0.045B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Edesa Biotech, Inc. (EDSA)Canada$0.039B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
CervoMed Inc. (CRVO)United States$0.038B-1.39
Celularity Inc (CELU)United States$0.038B-0.34